Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

What Was Tested

The trial (phase 3) is built around Insulin Glargine.

It had two arms (groups): basal insulin plus glucose lowering drugs (active comparator) and glucose lowering drugs only (active comparator).

The registry classes the interventions as drug.

More on the Plan

Despite the development of new drugs and therapeutic strategies for treating type 2 diabetes mellitus (T2DM), achieving long-term glycemic control remains a challenge.

However, these studies applied complex regimes for insulin initiations that require frequent follow-up and are difficult to accept as initial therapy for T2DM.

Who Took Part

The registry lists 243 actual participants took part.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Newly diagnosed type 2 diabetes mellitus on no glucose-lowering drugs and.

The full record lists 2 inclusion and 6 exclusion criteria; among the exclusions: patients with type 1 diabetes mellitus,; urine ketone dipstick + and above at baseline or anytime throughout the study; current or recent steroid use.

How the Study Was Run

It was run as a non-randomized, parallel-group and open-label study.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2023-11-01 with completion listed for 2024-11-01.

It ran at 1 site in Iraq.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in hemoglobin A1c (time frame: three months). Change in hemoglobin A1c (time frame: six months). Change in hemoglobin A1c (time frame: twelve months).

It also tracked 1 secondary outcome, for example Hypoglycemia.

What This Means in Plain Language

Put simply, this is a phase 3, non-randomized trial of Insulin Glargine in 243 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin Glargine compound page, all human trials.